Enzon Pharma Inc (ENZN) 0.3950 $ENZN Xerox Adds New

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Enzon Pharma Inc (ENZN) 0.3950 $ENZN

Xerox Adds New Director to its Board
BusinessWire - Mon Jun 27, 3:30PM CDT
Xerox (NYSE:XRX) and Carl C. Icahn announced today that they have entered into an agreement under which Jonathan Christodoro has been appointed to the Xerox board of directors effective immediately. Mr. Christodoro will also join the board's corporate governance committee and finance committee. With the addition, the Xerox board is now comprised of nine directors. Additional details regarding the agreement will be included in a Form 8-K to be filed by Xerox later today.
HLF: 61.04 (+0.91), LNG: 37.66 (+0.56), XRX: 9.54 (+0.16)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Delaware Law by the Board of Enzon Pharmaceuticals Inc.
PR Newswire - Wed Jan 27, 11:24AM CST
Levi & Korsinsky announces it has commenced an investigation of Enzon Pharmaceuticals Inc. (NASDAQ: ENZN) concerning possible breaches of Delaware law by the board of directors of the company. To obtain additional information, go to:

Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant
Marketwired - Mon Nov 30, 6:30AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, announced today that Ronald Trust, PhD, MBA, has been retained as a consultant to the Company to oversee regulatory affairs pertaining to the planned Brilacidin Phase 3 program for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), among other responsibilities.
AGN: 240.59 (+2.58)

Biotechnology Stocks Technical Study -- Exelixis, XOMA Corp., Enzon Pharma, Peregrine Pharma, and StemCells
PR Newswire - Mon Sep 21, 7:50AM CDT
Equity Research Institute has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and StemCells Inc. (NASDAQ: STEM). Free research report on Exelixis can be accessed at https://www.erionline.net/EXEL.pdf On Friday, September 18, 2015, the NASDAQ Composite ended at 4,827.23, down 1.36%, the Dow Jones Industrial Average declined 1.74%, to finish the day at 16,384.79, and the S&P 500 closed at 1,958.03, down 1.62%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
STEM: 0.40 (unch), PPHM: 0.39 (+0.01), XOMA: 0.55 (+0.01), EXEL: 8.15 (+0.01)

Guidance & Quarterly Review on Four Biotech Companies
ACCESSWIRE - Fri Aug 14, 6:00AM CDT
NEW YORK, NY / ACCESSWIRE / August 14, 2015 / Four biotechnology companies reported earnings last week. These companies include Synta Pharmaceuticals (NASDAQ: SNTA), TransEnterix, Inc., (NYSE-MKT: TRXC), Xoma Corp (NASDAQ: XOMA) and Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN).
SNTA: 0.28 (unch), TRXC: 1.27 (+0.09), XOMA: 0.55 (+0.01)

Technical Coverage on Biotechnology Equities -- Achillion Pharma, CTI BioPharma, Enzon Pharma, Discovery Laboratories, and Pacific Biosciences of California
PR Newswire - Mon Jul 20, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), CTI BioPharma Corporation (NASDAQ: CTIC), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Discovery Laboratories Inc. (NASDAQ: DSCO), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Free research report on Achillion Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ACHN On Friday, July 17, 2015, the NASDAQ Composite ended at 5,210.14, up 0.91%, the Dow Jones Industrial Average declined 0.19%, to finish the day at 18,086.45, and the S&P 500 closed at 2,126.64, up 0.11%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
PACB: 7.53 (+0.20), ACHN: 9.14 (+0.26), CTIC: 0.35 (-0.01), DSCO: 3.50 (-0.36)

Technical Scrutiny on Biotech Stocks -- ARIAD Pharma, Array BioPharma, Enzon Pharma, Ironwood Pharma, and Regulus Therapeutics
PR Newswire - Tue May 12, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
IRWD: 13.37 (+0.25), RGLS: 3.50 (+0.07), ARIA: 7.51 (+0.17), ARRY: 3.71 (+0.03)

Health of Health Care Stocks: Complementary Research on Enzon Pharmaceuticals, Durect Corporation, Vertex Pharmaceuticals, Advaxis, and Omnicare
PR Newswire - Fri Apr 24, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
OCR: 97.90 (-0.02), ADXS: 8.61 (+0.04), VRTX: 88.96 (-1.09), DRRX: 1.27 (+0.07)

Nasdaq stocks posting largest volume increases
AP - Thu Apr 23, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CALI: 2.26 (+0.21), PCMI: 11.20 (+0.07), URRE: 1.67 (+0.04), HMTV: 12.02 (+0.24), SCYX: 2.21 (+0.03), ARTW: 3.06 (+0.01), PKT: 11.50 (+0.02), PLMT: 19.25 (unch), MNRK: 18.49 (-1.37)

Most active Nasdaq-traded stocks
AP - Thu Apr 23, 5:05PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 12.62 (+0.42), AMD: 5.10 (+0.08), FB: 117.24 (+1.39), BRCM: 54.67 (+0.17), TXN: 63.27 (+1.50), CMCSK: 58.00 (-1.69), MSFT: 52.30 (+0.92), INTC: 34.00 (+0.80), VLTC: 3.44 (+0.01), CMCSA: 67.11 (+0.85), AAPL: 96.68 (+0.74), CSCO: 29.26 (+0.52)

Key Trends in the Pharmaceutical and Nutritional Supplement Industries Outperforming Other Industries as Increase in Pharma Grade Products & Supplements Grow Globally
PR Newswire - Wed Apr 22, 7:35AM CDT
The Worldwide nutritional supplement market, segmented into groups such as vitamins, pharma grade supplements, protein supplements, probiotics, fish oils, blended supplements, is driven by factors such as increasing global health consciousness and growing consumer income. Some analyst forecasts that the global dietary supplements market was valued at $60 Billion in 2014 and is expected to reach $80 Billion by 2020. Nutrition & Pharma Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Vitamin Shoppe (NYSE:VSI), Herbalife Ltd. (NYSE: HLF) and Enzon Pharmaceuticals (NASDAQ: ENZN)
HLF: 61.04 (+0.91), VSI: 31.79 (+0.82), GNC: 25.53 (+0.81), MYL: 44.54 (+0.84), TEVA: 50.89 (+0.37)

A Look at the Health of the HealthCare Sector: Complementary Research on Horizon Pharma, Enzon Pharmaceuticals, Momenta Pharmaceuticals, Athersys, and Pernix Therapeutics
PR Newswire - Tue Apr 21, 9:46AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PTX: 0.55 (+0.06), HZNP: 18.71 (+0.52), ATHX: 2.29 (+0.05), MNTA: 11.41 (+0.20)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 98

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 63

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 146

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
PZZA Faces Class Action: Strategic Shake-up or Misstep?

Updated Category News Views 10

Papa John's: Doughy Deceit or Strategic Misfire? Once in a while, a corporation trips over its own ambitious production line, and Papa John’s (NASDAQ:PZZA) is the latest contestant to make headlines for all the wrong reasons. Investors in this pizza powerhouse are being called to the courtroom as a class action lawsuit unfolds, marking a turbulent stage in the...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 79

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 125

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Beta Bionics Faces Class Action Lawsuit Amid FDA Concerns

Updated Category News Views 240

Beta Bionics in the Legal Crosshairs When a company like Beta Bionics gets hauled into court, you know it's not just smoky mirrors and boardroom politics. The stakes are high right now, with investors lining up for a class-action lawsuit that zeroes in on a nasty bundle of allegations. This isn't just a blip on the radar. It's a seismic wave in the industry. Allegations...

Continue Reading
Wisconsin Brats Clash with Florida Citrus in Marketing Showdown

Updated Category News Views 26

A Juicy Rivalry with Sweet and Savory Stakes You ever catch yourself watching state pride turn into a marketing showdown? That's what's cookin' with Wisconsin's Johnsonville and Florida's Natural, and believe me, this isn't just about what’s on your plate. Forget the foam fingers, here it's all about the brats and the OJ. It's like the Packers versus the Dolphins, but...

Continue Reading
Pathalys' Phase 3 Data Shows Promise for CKD Drug

Updated Category News Views 63

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

Continue Reading
DigitalXForce Booms with 514% Growth and Major Backing

Updated Category News Views 184

Massive Growth and Strategic Investment in DigitalXForce Now here’s a company that’s shaking things up—DigitalXForce. Right on the back of a staggering 514% growth, they’ve corralled a strategic investment from Arsenal Growth Equity. If you blink, you might miss just how fast they’re sprinting through the tech landscape. Institutional Support Backing the...

Continue Reading

Top 5 Most Recently Viewed Articles

California Science Center Celebrates Topping Out New Space Center

Updated Category News Views 338

California Science Center Celebrates Construction Milestone The California Science Center has recently achieved a remarkable milestone in the construction of the future Samuel Oschin Air and Space Center. The topping out ceremony celebrated the placement of some of the final steel beams in the innovative diagrid roof structure, which is set to become an iconic part of the...

Continue Reading
Analysis of Trump's Tax Proposal: Who Benefits Most?

Updated Category News Views 355

Trump's tax proposal hit the scene back in 2024, causing a storm of chatter among traders and economists. The thing was a mixed bag—while it looked like a goldmine for the wealthy, everyone else seemed to be left holding the short end of the stick. The Wealth Disparity Play: Tax Cuts or Tax Burdens? A detailed analysis from ITEP threw some serious numbers into the ring....

Continue Reading
MotherDuck Launches pg_duckdb to Revolutionize PostgreSQL Queries

Updated Category News Views 194

MotherDuck Introduces pg_duckdb for Enhanced Analytics MotherDuck is making waves in the data analytics world with the launch of its new PostgreSQL extension called pg_duckdb. This innovative tool brings the robust analytics capabilities of DuckDB right into the PostgreSQL environment, allowing businesses to execute sophisticated analytical queries without disrupting...

Continue Reading
Intel Corporation's Strategic Moves and Stock Performance Unveiled

Updated Category News Views 227

Intel Corporation's Latest Stock Surge Intel Corporation (NASDAQ: INTC) achieved an impressive stock gain of 4.84%, closing at $23.07 on a recent trading day. This surge reflects the company's vigorous restructuring efforts aimed at redefining its business operations. As industry dynamics shift, Intel is undergoing significant transformations to bolster its market...

Continue Reading
EagleView Introduces Comprehensive Property Data Ecosystem

Updated Category News Views 183

EagleView Brings Forth an Innovative Property Data Solution EagleView, a prominent player in aerial imagery, has unveiled its latest property data ecosystem, a significant leap forward in how property insights can be gathered and utilized. This new initiative encompasses over 60 petabytes of data, derived from high-definition aerial imagery, designed to provide invaluable...

Continue Reading